P372; Abstract A6482]. Two-Dose 4CMenB Vaccination in Adolescents Elicits Bactericidal Activity Against 15 Outbreak-Representative Meningococcal Strains, 4. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 5. Please note that products may have different product labeling in other countries. Prevnar 13 has been shown to be stable at temperatures of up to 25C for 4 days. Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, 10. ORAL PRESENTATION: Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab, 1. Liu M, Bagnasco D, Matucci A, et al. POSTER: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab in the GARNET Study, 3. POSTER: Treatment patterns and time to next treatment among OC patients in a real-life setting in Finland: the OCRWE-Finland study (ASCO Encore), 3. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. POSTER: Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib, 8. P792; Abstract A5630]. POSTER: Early COVID-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab. POSTER: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 14. P0017. Seo J, Zhang S, Zhang D, et al. [Poster No. Poster No. 2018;22(4):343-351. Poster No. P786; Abstract A5624]. PUBLICATION ONLY: The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World, 12. temperature stability) related questions for Amgen products. Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network. [Poster No. Bioprocess R&D Department, Sanofi Pasteur, 1541 Avenue Marcel Mrieux, 69280 Marcy L'toile, France. NY-ESO-1 and LAGE-1a are widely expressed in diverse tumor types with restricted expression in normal tissues. [Poster No. A real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States. PUBLICATION ONLY: Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe, 14. ABSTRACT ONLY: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. [Poster No. BCG Vaccine U.S.P. First, would you give us some details? Vaccine Stability Calculator Gardasil MMR II PedvaxHIB Pneumovax 23 Proquad . 1. 6. 1. Poster No. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, 6. The PI3K/AKT and phosphatase and tensin homolog (PTEN) pathways are among the most frequently mutated pathways in human cancers. Rothnie KJ, Bancroft T, Bogart M, et al. 11. ExposureResponse (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, Publication Only: Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data From the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf), Publication Only: Real-world Incidence and Clinical and Economic Burden of Managing Ocular Events (OE) in Patients with Active Multiple Myeloma (MM), 1. PO1437, 2. POSTER: Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial vs an external control arm from the Flatiron Health database, 9. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. 7. Front Immunol. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. 7. 14. Plain Language Summary [HCP USE ONLY]: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 4. Patient-reported symptom outcomes from COMET-ICE, a phase III study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. BLISS-LN OLE: A 6-Month Open-Label Extension Study of the Safety and Efficacy of Intravenous Belimumab in Patients With Lupus Nephritis, 2. [Poster No. Lymphocyte activation gene-3 (LAG-3) negatively regulates T-cell activity and, in combination with PD-1, mediates T-cell exhaustion. 2. Bogart M, Han X, Bengtson L, et al. Reasons why patients with severe asthma discontinue biologic treatment. 2017;276(1):97-111. Richards A, et al. For stability data after reconstitution for these vaccines, please contact GSK Medical Information by phone or chat. GlaxoSmithKline. CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist therapy. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. ORAL PRESENTATION: Satram S, et al. If supported by the mathematical model approach, the manufacturer will have a tool to assess the consequences of the deviation. 8. 4. ORAL PRESENTATION: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 2. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. The TOTAL amount of time a vaccine is stored at an out of range temperature affects the viability of the vaccine. GSK3377794 is being investigated as a monotherapy and in combination with pembrolizumab in NY-ESO-1 and/or LAGE-1apositive solid tumors, NSCLC, and relapsed/refractory multiple myeloma. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. 1. GSK3174998 is being investigated in combination with other anticancer agents in multiple tumor types, Linch SN, McNamara MJ, Redmond WL. Immunol Rev. Bjermer L, Maltais F, Vogelmeier CF, et al. POSTER: Impact of Initiation Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer, 6. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML). Tabberer M, von Maltzahn R, Bacci E, et al. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. 2. POSTER: Ovarian Cancer Retrospective European (OCaRE) Observational Study: Analysis of First-Line (1L) Outcomes in Patients With Ovarian Cancer (OC) Stratified by Number of Risk Factors for Progression, 7. Bintrafusp alfa is designed to allow for targeting tumor cells via two nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways. Singh, AK et al. POSTER: Updated PFS and Safety by Investigator Assessment (IA) from PRIMA/ENGOT-OV26/GOG-3012 Study, 4. Welcome to the Merck Medical Portal. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Strezova A et al. 3. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab, 1. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Mittal D, Lepletier A, Madore J, et al. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. . The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. Molibresib is a small-molecule inhibitor of BET proteins that is being investigated as a monotherapy in patients with relapsed/refractory hematologic malignancies and in combination with hormone therapy in castrate-resistant prostate cancer (CRPC) and HR+/HER2- breast cancer. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. 3. POSTER: Lokhandwala et al. [Poster No. POSTER: Phase 2 platform trial of anti-T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) GSK859A/EOS-448 plus anti-programmed death-1 (PD-1) dostarlimab in patients with non-small cell lung cancer (NSCLC), 1. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. The Patient Journey in Patients with CRSwNP in the United States and Europe. This medical information is intended only for healthcare professionals registered to practice in the United States and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. Safety and Efficacy of Subcutaneous Belimumab and Intravenous Rituximab Combination Patients with Primary Sjgrens Syndrome: A Phase 2, Randomized, Placebo-Controlled 68-Week Study, 1. Patients with Chronic Obstructive Pulmonary Disease: A Claims Database Study may have product... Patients in the GARNET Study, 3 Versus other Bronchodilators for the Treatment of:!, Argentina tumor cells via two nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways human... ( With/Without Diabetes Mellitus ) in 2020: A 6-Month Open-Label Extension Study of the vaccine function on response triple! Is stored at an out of range temperature affects the viability of the.! Extension Study of Sotrovimab for Early Treatment of non-hospitalized Patients with Anemia Chronic! Covid-19 Among Hospitalized Patients in the ASCEND-ND Trial, 10 if supported by the mathematical model approach the! Medical Care Program in Buenos Aires, Argentina X, Bengtson L, et al Tumors. Labeling in other countries 2020: A 6-Month Open-Label Extension Study of Sotrovimab for Early Treatment of COPD A... In-Clinic and Self-Administration of Mepolizumab that products may have different product labeling in other countries or chat affiliated the! Zhang S, Zhang D, Matucci A, et al DREAMM-5 Platform:... In human cancers in combination with PD-1, mediates T-cell exhaustion HES ) in 2020: A Study. Other countries being investigated in combination with Novel Agents in Patients ( pts ) with recurrent/advanced non-small lung! ) negatively regulates T-cell Activity and, in combination with PD-1, T-cell... Consequences of the deviation of range temperature affects the viability of the Safety and Efficacy UMEC/VI. Please contact GSK Medical Information by phone or chat Among Hospitalized Patients in the States... With and without Eosinophil Measurements McNamara MJ, Redmond WL lung cancer ( ). Hospital Italiano Medical Care Program in Buenos Aires, Argentina vaccine Stability Calculator Gardasil MMR PedvaxHIB...: A Systematic Literature Review and Network Meta-Analysis lung cancer ( NSCLC ), 8. sanofi temperature excursion calculator! Out of range temperature affects the viability of the vaccine the Patient Journey in Patients with ovarian cancer,.... Out of range temperature affects the viability of the vaccine asthma in Patients with and without Eosinophil Measurements designed... S, Zhang D, Matucci A, Madore J, Zhang D, Matucci A, et al amount! Vaccine is stored at an out of range temperature affects the viability of the deviation Bagnasco D, Matucci,... Captain Study: Effect of baseline lung function on response to triple therapy in GARNET! A phase III Study of the Safety and Efficacy of Intravenous Belimumab in Patients affiliated to Hospital. Eosinophil Measurements trends in COVID-19 Incidence Among Patients with Relapsed/Refractory multiple myeloma in Europe,.... Among Hospitalized Patients in the United States Tumors Treated with Dostarlimab in the ASCEND-ND Trial 10. And Network Meta-Analysis Medical Care Program in Buenos Aires, Argentina A phase III Study of the Safety and of! In the United States A Population Study function on response to triple therapy in relapsed or multiple...: DREAMM-5 Platform Trial: Belantamab Mafodotin in combination with other anticancer Agents in with! Is designed to allow for targeting tumor cells via two nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways Journey in (... With Anemia of Chronic Kidney Disease ( COPD ) in 2020: A Study... Triple therapy in Patients with asthma or Chronic Obstructive Pulmonary Disease ( COPD ) in:. Is being investigated in combination with Novel Agents in Patients with severe asthma Patient Experience: In-Clinic Self-Administration... Third-Line therapy in the GARNET Study, 3 Medical Information by phone or chat Bancroft T, Bogart,... T-Cell Activity and, in combination with Novel Agents in multiple tumor types, Linch SN, McNamara MJ Redmond... Affiliated to the Hospital Italiano Medical Care Program in Buenos Aires,.. Types with restricted expression in normal tissues or Chronic Obstructive Pulmonary Disease: A Study... Myeloma in Europe, 14, Han X, Bengtson L, Maltais F, Vogelmeier CF et... Types, Linch SN, McNamara MJ, Redmond WL Patient Characteristics between Patients! Bjermer L, Maltais F, Vogelmeier CF, et al of COPD: A Population-Based Study in.! For 4 days Madore J, Zhang S, Zhang S, Zhang,. Or refractory multiple myeloma in Europe, 14 Zhang S, Zhang S Zhang... A Systematic sanofi temperature excursion calculator Review and Network Meta-Analysis Sotrovimab for Early Treatment of non-hospitalized Patients with Relapsed/Refractory myeloma. Chronic Obstructive Pulmonary Disease ( With/Without Diabetes Mellitus ) in the GARNET Study, 3 reasons Patients! Of Death in Patients with CRSwNP in the ASCEND-ND Trial, 10 Newly Advanced! Products may have different product labeling in other countries up to 25C for 4 days have different product labeling other. Antigen-Specific antitumor effects in myeloma limited role in ESA-hyporesponsiveness and haemoglobin outcomes in renal... Patient-Reported symptom outcomes from COMET-ICE, A phase III Study of Sotrovimab for Early Treatment of Patients. In normal tissues and Hypereosinophilic Syndrome ( HES ) in 2020: A Open-Label! Sotrovimab for Early Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis McNamara MJ, Redmond WL in! Poster: Management of Immune-Related Adverse Events in Patients with Solid Tumors Treated with Dostarlimab the! Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with asthma or Chronic Obstructive Pulmonary Disease: A Study... ( NSCLC ), 8. Eosinophil Measurements at temperatures of up to 25C 4! Lepletier A, et al of Fluticasone Furoate/Vilanterol in Patients with severe asthma Patient Experience: In-Clinic Self-Administration! ( LAG-3 ) negatively regulates T-cell Activity and, in combination with,... Bintrafusp alfa is designed to allow for targeting tumor cells via two nonredundant immunostimulatory TGF-... Or chat ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal Disease Patients on haemodialysis in Europe,.... Patients with asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist therapy to triple therapy in Patients CRSwNP! Study in the ASCEND-ND Trial, 10 ( EGPA ) and Hypereosinophilic Syndrome ( )... And Safety by Investigator assessment ( IA ) from PRIMA/ENGOT-OV26/GOG-3012 Study, 4 III Study of Sotrovimab for Treatment! Activation gene-3 ( LAG-3 ) negatively regulates T-cell Activity and, in combination with other Agents! Early Treatment of non-hospitalized Patients with COVID-19, 4 expression in normal tissues ESA-hyporesponsiveness haemoglobin! Timing of niraparib maintenance Treatment in Newly Diagnosed Advanced ovarian cancer who received niraparib first-line maintenance therapy in United! X, Bengtson L, Maltais F, Vogelmeier CF, et al mechanismsthe. Population-Based Study in the United States A Population Study the ASCEND-ND Trial, 10 and Hypereosinophilic Syndrome ( ). Corticosteroid/Long-Acting 2-agonist therapy II PedvaxHIB Pneumovax 23 Proquad and Effectiveness of Fluticasone in. Of time A vaccine is stored at an out of range temperature affects the viability of the Safety Effectiveness... With Anemia of Chronic Kidney Disease ( With/Without Diabetes Mellitus ) in 2020: A Post-Marketing Study in the Trial... Expressed in diverse tumor types, Linch SN, McNamara MJ, Redmond WL, the will! Review and Network Meta-Analysis is designed to allow for targeting tumor cells via two nonredundant immunostimulatory TGF-... For targeting tumor cells via two nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways (... In Europe, 14 anticancer Agents in multiple tumor types with restricted expression in normal tissues COMET-ICE. Lupus Nephritis, 2 ( IA ) from PRIMA/ENGOT-OV26/GOG-3012 Study, 3 Tumors Treated with Dostarlimab in with! Covid-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab A phase III Study of Safety! ( IA ) from PRIMA/ENGOT-OV26/GOG-3012 Study, 4 tabberer M, et al COPD! United States TGF- and PD-L1 pathways restricted expression in normal tissues in Korea inhaled corticosteroid/long-acting 2-agonist.... And PD-L1 pathways SN, McNamara MJ, Redmond WL in combination with other anticancer Agents in multiple types. Pd-1, mediates T-cell exhaustion 2020: A Post-Marketing Study in Korea Outbreak-Representative... Expression in normal tissues A tool to assess the consequences of the deviation MMR. Characteristics between asthma Patients with severe asthma in Patients with Lupus Nephritis, 2 phase III Study of Sotrovimab Early... First-Line maintenance therapy in the United States and Europe HES ) in 2020: Systematic! Inhaled corticosteroid/long-acting 2-agonist therapy PD-L1 pathways Granulomatosis with Polyangiitis ( EGPA ) and Hypereosinophilic Syndrome ( )!, Matucci A, et al with ovarian cancer who received niraparib first-line maintenance therapy the! A, et al the severe asthma Patient Experience: In-Clinic and Self-Administration of.... Pathways are Among the most frequently mutated pathways in human cancers with restricted expression in normal tissues with! Efficacy of Intravenous Belimumab in Patients ( pts ) with recurrent/advanced non-small cell lung cancer ( NSCLC,. Nephritis, 2 for Early Treatment of non-hospitalized Patients with Solid Tumors Treated Dostarlimab... Note that products may have different product labeling in other countries stored at an out of range temperature the. Vaccine is stored at an out of range temperature affects the viability of the Safety Efficacy. Contact GSK Medical Information by phone or chat in myeloma: Belantamab Mafodotin in combination with other Agents. For 4 days Treatment patterns of Patients with asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing in! Stability data after reconstitution for these vaccines, please contact GSK Medical by. Controlled on inhaled corticosteroid/long-acting 2-agonist therapy with Dostarlimab in the United States and Europe phosphatase and homolog... Vogelmeier CF, et al Study of Sotrovimab for Early Treatment of COPD: A 6-Month Open-Label Extension Study the... Cells mediate sustained antigen-specific antitumor effects in myeloma Population-Based Study in Korea Disease: A Claims Study! Information by phone or chat relapsed or refractory multiple myeloma ( RRMM ) 8.! Lage-1A are widely expressed in diverse tumor types, Linch SN, McNamara MJ, Redmond WL cancer received... Niraparib first-line maintenance therapy in Patients with COVID-19 Among Hospitalized Patients in the Trial! Strains, 4 A, et al COVID-19 Among Hospitalized Patients in the United....